-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Maze Therapeutics, Maintains $48 Price Target

Benzinga·09/23/2026 12:17:30
语音播报
Wedbush analyst Laura Chico reiterates Maze Therapeutics (NASDAQ:MAZE) with a Outperform and maintains $48 price target.